

Taku Kobayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3388404/publications.pdf>

Version: 2024-02-01

130
papers

6,360
citations

101384

36
h-index

74018

75
g-index

135
all docs

135
docs citations

135
times ranked

7722
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. <i>Intestinal Research</i> , 2023, 21, 110-125.	1.0	9
2	Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 200-207.	0.9	4
3	Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 27-38.	0.6	66
4	Stopping Anti-TNF in CD Remitters: Cons. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 1-5.	0.8	0
5	Safety and efficacy of the endoscopic delivery of capsule endoscopes in adult and pediatric patients: Multicenter Japanese study (AdvanCE study). <i>Digestive Endoscopy</i> , 2022, 34, 543-552.	1.3	8
6	Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 21-31.	0.9	14
7	Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials. <i>Gastroenterology</i> , 2022, 162, 482-494.	0.6	46
8	Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 171-185.	3.7	57
9	Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). <i>Journal of Gastroenterology</i> , 2022, 57, 174-184.	2.3	8
10	Lack of Increased Risk of Lymphoma with Thiopurine Therapy Regardless of Dose and Duration of Treatment in Japanese Patients with Inflammatory Bowel Diseases. <i>Digestion</i> , 2022, 103, 169-173.	1.2	4
11	Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1320-1329.	1.9	8
12	AJM300 (carotegrast methyl), an oral antagonist of $\alpha 4$ -integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 648-657.	3.7	38
13	Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1569-1580.	1.9	8
14	Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis—an accurate early predictor of response to treatment. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1204-1205.	1.9	1
15	Editorial: is older-onset ulcerative colitis more severe or less aggressively managed? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1352-1353.	1.9	1
16	Certolizumab pegol for maintenance of medically induced remission in Crohn's disease. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	3
17	Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1130-1141.	0.6	37
18	Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. <i>Digestive Diseases and Sciences</i> , 2021, 66, 577-586.	1.1	21

#	ARTICLE	IF	CITATIONS
19	Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 908-921.e6.	2.4	38
20	Does anti-tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 864-872.	1.4	7
21	Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial. <i>Journal of Gastroenterology</i> , 2021, 56, 147-157.	2.3	13
22	Intestinal cancer in patients with Crohn's disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 329-336.	1.4	15
23	Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 943-950.	1.4	10
24	Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2116-2124.	1.4	4
25	Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1744-1753.	1.4	5
26	Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 489-526.	2.3	202
27	Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. <i>Journal of Gastroenterology</i> , 2021, 56, 560-569.	2.3	34
28	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2021, 9, 451-460.	1.6	31
29	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 482-497.	3.7	28
30	Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 429-437.	3.7	34
31	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 857-873.	8.2	56
32	Stringent criteria for withdrawal of biologics in ulcerative colitis – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 688.	3.7	0
33	Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation. <i>Journal of Gastroenterology</i> , 2021, 56, 999-1007.	2.3	3
34	Endoscopic evaluation after surgery in inflammatory bowel disease – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 691-692.	3.7	0
35	The dietary practices and beliefs of people living with inactive ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 372-379.	0.8	30
36	Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis. <i>Intestinal Research</i> , 2021, 19, 448-460.	1.0	11

#	ARTICLE	IF	CITATIONS
37	A nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 1062-1079.	2.3	5
38	Development of algorithms for identifying patients with Crohn's disease in the Japanese health insurance claims database. <i>PLoS ONE</i> , 2021, 16, e0258537.	1.1	5
39	OUP accepted manuscript. <i>Journal of Crohn's and Colitis</i> , 2021, , .	0.6	6
40	Validation of a claims-based algorithm to identify cases of ulcerative colitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, , .	1.4	4
41	Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. <i>Inflammatory Intestinal Diseases</i> , 2021, 6, 186-198.	0.8	2
42	Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 562-572.e12.	0.6	173
43	Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. <i>Journal of Gastroenterology</i> , 2020, 55, 169-180.	2.3	23
44	Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1102-1111.e5.	2.4	29
45	Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 225-232.	1.4	14
46	Lack of Increased Risk of Lymphoma by Thiopurines or Biologics in Japanese Patients with Inflammatory Bowel Disease: A Large-Scale Administrative Database Analysis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 617-623.	0.6	26
47	Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis—“one more arrow in the quiver of non-invasive diagnostics. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 403-403.	1.9	2
48	Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor- α Inhibitor Induction Therapy among Patients with Crohn's Disease. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 78-83.	0.8	6
49	Ulcerative colitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 74.	18.1	678
50	Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1373-1383.	1.9	50
51	Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet's disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants. <i>Journal of Gastroenterology</i> , 2020, 55, 679-700.	2.3	39
52	Inflammatory Bowel Disease in Japan-Is It Similar to or Different from Westerns?-. <i>Journal of the Anus, Rectum and Colon</i> , 2020, 4, 1-13.	0.4	21
53	Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 393-405.	3.7	78
54	A nationwide, multi-center, retrospective study of symptomatic small bowel stricture in patients with Crohn's disease. <i>Journal of Gastroenterology</i> , 2020, 55, 615-626.	2.3	12

#	ARTICLE	IF	CITATIONS
55	Ulcerative Colitis: Disease Burden, Impact on Daily Life, and Reluctance to Consult Medical Professionals: Results from a Japanese Internet Survey. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 27-35.	0.8	29
56	Capsule endoscopy in inflammatory bowel disease: when and how. <i>Intestinal Research</i> , 2020, 18, 265-274.	1.0	13
57	Mechanism-Based Treatment Strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and More. <i>Inflammatory Intestinal Diseases</i> , 2019, 4, 79-96.	0.8	53
58	Mo1669 NATIONWIDE MULTICENTER PROSPECTIVE STUDY ON USEFULNESS, SAFETY, AND ACCEPTABILITY OF COLON CAPSULE ENDOSCOPY IN JAPAN. <i>Gastrointestinal Endoscopy</i> , 2019, 89, AB513-AB514.	0.5	0
59	Phosphoinositide 3-Kinase P110 γ -Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation. <i>Cells</i> , 2019, 8, 1121.	1.8	15
60	Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2019, 9, e024222.	0.8	4
61	Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. <i>PLoS ONE</i> , 2019, 14, e0212404.	1.1	9
62	P078 CAPSULE SCORING OF ULCERATIVE COLITIS (CSUC) IS USEFUL FOR MONITORING INACTIVE ULCERATIVE COLITIS. <i>Inflammatory Bowel Diseases</i> , 2019, 25, S37-S37.	0.9	0
63	Certolizumab pegol for induction of remission in Crohn's disease. <i>The Cochrane Library</i> , 2019, 2019, CD012893.	1.5	6
64	Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients. <i>Intestinal Research</i> , 2019, 17, 87-93.	1.0	8
65	Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. <i>Intestinal Research</i> , 2019, 17, 218-226.	1.0	2
66	Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. <i>Intestinal Research</i> , 2019, 17, 504-515.	1.0	14
67	Safety and efficacy of leukocytapheresis in elderly patients with ulcerative colitis: The impact in steroid-free elderly patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1485-1491.	1.4	16
68	Evidence-based clinical practice guidelines for inflammatory bowel disease. <i>Journal of Gastroenterology</i> , 2018, 53, 305-353.	2.3	427
69	Th17 plasticity and its relevance to inflammatory bowel disease. <i>Journal of Autoimmunity</i> , 2018, 87, 38-49.	3.0	214
70	Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2018, 154, 935-947.	0.6	139
71	A Simple 1-Day Colon Capsule Endoscopy Procedure Demonstrated to be a Highly Acceptable Monitoring Tool for Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2404-2412.	0.9	16
72	A multicenter, retrospective, observational study of the clinical outcomes and risk factors for relapse of ulcerative colitis at 1 year after leukocytapheresis. <i>Journal of Gastroenterology</i> , 2018, 53, 387-396.	2.3	13

#	ARTICLE	IF	CITATIONS
73	Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1031-1038.	1.4	24
74	Endoscopic Indices for Ulcerative Colitis. , 2018, , 163-172.		0
75	Risk Factors for Mortality in <i>Pneumocystis jirovecii</i> Pneumonia in Patients with Inflammatory Bowel Disease. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 167-172.	0.8	9
76	Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 1-10.	0.8	4
77	Drug Lag for Inflammatory Bowel Disease Treatments in the East and West. <i>Inflammatory Intestinal Diseases</i> , 2018, 3, 25-31.	0.8	8
78	Establishment of a Novel Scoring System for Colon Capsule Endoscopy to Assess the Severity of Ulcerative Colitis—Capsule Scoring of Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2641-2647.	0.9	19
79	Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1288-1294.	0.6	58
80	NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. <i>Journal of Gastroenterology</i> , 2018, 53, 1065-1078.	2.3	86
81	Seven days triple therapy for eradication of <i>Helicobacter pylori</i> does not alter the disease activity of patients with inflammatory bowel disease. <i>Intestinal Research</i> , 2018, 16, 609-618.	1.0	12
82	Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries. <i>Intestinal Research</i> , 2018, 16, 168.	1.0	8
83	Endocytoscopy can be used to assess histological healing in ulcerative colitis. <i>Endoscopy</i> , 2017, 49, 560-563.	1.0	38
84	Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2245-2251.	0.9	15
85	Involvement of herbal medicine as a cause of mesenteric phlebosclerosis: results from a large-scale nationwide survey. <i>Journal of Gastroenterology</i> , 2017, 52, 308-314.	2.3	35
86	Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission-induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. <i>PLoS ONE</i> , 2017, 12, e0185131.	1.1	16
87	Steroid-refractory extensive enteritis complicated by ulcerative colitis successfully treated with adalimumab. <i>Intestinal Research</i> , 2017, 15, 535.	1.0	1
88	A case of gastric mucosal prolapse polyp that was difficult to differentiate from duodenal submucosal tumor. <i>Progress of Digestive Endoscopy</i> , 2016, 88, 106-107.	0.0	0
89	Lipocalin 2 prevents intestinal inflammation by enhancing phagocytic bacterial clearance in macrophages. <i>Scientific Reports</i> , 2016, 6, 35014.	1.6	49
90	First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. <i>Journal of Gastroenterology</i> , 2016, 51, 241-251.	2.3	93

#	ARTICLE	IF	CITATIONS
91	Usefulness of Fecal Calprotectin in Detecting the Early Response to Induction Therapy in Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2016, 111, S330.	0.2	0
92	First Trough Level of Infliximab at Week 2 Predicts Future Outcomes of Induction Therapy in Ulcerative Colitis: A Post-hoc Analysis of a Multicenter Prospective Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2015, 110, S787.	0.2	1
93	Effects of CYP3A5 Genotype on Efficacy and Safety of Tacrolimus in Refractory Ulcerative Colitis: An Experience From a Tertiary Referral Center in Japan. <i>American Journal of Gastroenterology</i> , 2015, 110, S820.	0.2	1
94	Modified bowel preparation regimen for use in second-generation colon capsule endoscopy in patients with ulcerative colitis. <i>Digestive Endoscopy</i> , 2014, 26, 665-672.	1.3	24
95	NFIL3-Deficient Mice Develop Microbiota-Dependent, IL-12/23-Driven Spontaneous Colitis. <i>Journal of Immunology</i> , 2014, 192, 1918-1927.	0.4	41
96	Innate PI3K p110 β Regulates Th1/Th17 Development and Microbiota-Dependent Colitis. <i>Journal of Immunology</i> , 2014, 192, 3958-3968.	0.4	53
97	Which makes patients happier, surgery or anti-TNF therapy?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 272-273.	8.2	1
98	A large-scale, prospective, observational study of leukocytapheresis for ulcerative colitis: Treatment outcomes of 847 patients in clinical practice. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 981-991.	0.6	49
99	Changes in endoscopic findings in a case of primary gastric amyloidosis. <i>Progress of Digestive Endoscopy</i> , 2014, 84, 88-89.	0.0	0
100	Carbon Monoxide and Heme Oxygenase-1 Prevent Intestinal Inflammation in Mice by Promoting Bacterial Clearance. <i>Gastroenterology</i> , 2013, 144, 789-798.	0.6	102
101	In Vitro and In Vivo Evaluation of a Water-in-Oil Microemulsion System for Enhanced Peptide Intestinal Delivery. <i>AAPS Journal</i> , 2013, 15, 288-298.	2.2	27
102	Lectin-based Immunoassay for Aberrant IgG Glycosylation as the Biomarker for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 321-331.	0.9	33
103	Inducible colitis-associated glycome capable of stimulating the proliferation of memory CD4+ T cells. <i>Journal of Experimental Medicine</i> , 2012, 209, 2383-2394.	4.2	32
104	A Cell Permeable Peptide Inhibitor of NFAT Inhibits Macrophage Cytokine Expression and Ameliorates Experimental Colitis. <i>PLoS ONE</i> , 2012, 7, e34172.	1.1	50
105	IL-10 Regulates <i>IL12b</i> Expression via Histone Deacetylation: Implications for Intestinal Macrophage Homeostasis. <i>Journal of Immunology</i> , 2012, 189, 1792-1799.	0.4	68
106	Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2169-2179.	0.9	161
107	Nfil3 is a Regulator of IL-12 P40 in Macrophages and Mucosal Immunity. <i>Gastroenterology</i> , 2011, 140, S-109-S-110.	0.6	1
108	Epigenetic regulation of IL-12 p40 by IL-10 in intestinal immunity. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S11.	0.9	0

#	ARTICLE	IF	CITATIONS
109	Correlation between endocytoscopy and conventional histopathology in microstructural features of ulcerative colitis. <i>Journal of Gastroenterology</i> , 2011, 46, 1197-1202.	2.3	56
110	NFIL3 Is a Regulator of IL-12 p40 in Macrophages and Mucosal Immunity. <i>Journal of Immunology</i> , 2011, 186, 4649-4655.	0.4	101
111	An Anti-Inflammatory Role for Carbon Monoxide and Heme Oxygenase-1 in Chronic Th2-Mediated Murine Colitis. <i>Journal of Immunology</i> , 2011, 186, 5506-5513.	0.4	124
112	Characterization of an Interferon-stimulated Response Element (ISRE) in the IL23a Promoter. <i>Journal of Biological Chemistry</i> , 2011, 286, 1174-1180.	1.6	16
113	Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. <i>Journal of Gastroenterology</i> , 2010, 45, 936-943.	2.3	32
114	Rapid endoscopic improvement is important for 1-year avoidance of colectomy but not for the long-term prognosis in cyclosporine A treatment for ulcerative colitis. <i>Journal of Gastroenterology</i> , 2010, 45, 1129-1137.	2.3	38
115	TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 568-575.	0.9	105
116	Monocyte Chemoattractant Protein-1 Contributes to Gut Homeostasis and Intestinal Inflammation by Composition of IL-10-Producing Regulatory Macrophage Subset. <i>Journal of Immunology</i> , 2010, 184, 2671-2676.	0.4	128
117	Cutting Edge: IFN- γ Is a Negative Regulator of IL-23 in Murine Macrophages and Experimental Colitis. <i>Journal of Immunology</i> , 2010, 184, 4069-4073.	0.4	72
118	In vivo visualization of trophozoites in patients with amoebic colitis by using a newly developed endocytoscope. <i>Gastrointestinal Endoscopy</i> , 2010, 72, 643-646.	0.5	15
119	Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110 β . <i>Gastroenterology</i> , 2010, 139, 1642-1653.e6.	0.6	78
120	Human CD14 ⁺ Macrophages in Intestinal Lamina Propria Exhibit Potent Antigen-Presenting Ability. <i>Journal of Immunology</i> , 2009, 183, 1724-1731.	0.4	108
121	Dietary Histidine Ameliorates Murine Colitis by Inhibition of Proinflammatory Cytokine Production From Macrophages. <i>Gastroenterology</i> , 2009, 136, 564-574.e2.	0.6	139
122	Short- and Long-term Efficacy of Intravenous Cyclosporine in Severe Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2009, 104, S474.	0.2	0
123	Tetomilast suppressed production of proinflammatory cytokines from human monocytes and ameliorated chronic colitis in IL-10-deficient mice. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1483-1490.	0.9	18
124	IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. <i>Gut</i> , 2008, 57, 1682-1689.	6.1	470
125	Unique CD14 ⁺ intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN- γ axis. <i>Journal of Clinical Investigation</i> , 2008, 118, 2269-80.	3.9	559
126	Lamina Propria c-kit ⁺ Immune Precursors Reside in Human Adult Intestine and Differentiate Into Natural Killer Cells. <i>Gastroenterology</i> , 2007, 133, 559-573.	0.6	77

#	ARTICLE	IF	CITATIONS
127	Exclusive increase of CX3CR1+CD28 ^{hi} CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 837-846.	0.9	75
128	Monozygotic twins concordant for intestinal Behçet's disease. <i>Journal of Gastroenterology</i> , 2005, 40, 421-425.	2.3	23
129	Treatment Options after Anti-TNF Failure. <i>Frontiers of Gastrointestinal Research</i> , 0, , 229-233.	0.1	1
130	Usefulness of colestimide for diarrhea in postoperative Crohn's disease. <i>JGH Open</i> , 0, , .	0.7	0